Walleye Capital LLC Makes New $307,000 Investment in Janux Therapeutics, Inc. $JANX

Key Points

• Walleye Capital LLC has invested approximately $307,000 in Janux Therapeutics, acquiring 11,380 shares during the first quarter.
• Janux Therapeutics has received ratings from analysts, including an "overweight" rating with a price objective of $42.00 from Piper Sandler and a $65.00 price objective from Raymond James Financial.
• The company's stock shows a significant price fluctuation, with a one-year low of $21.97 and a high of $71.71, and it currently trades around $23.04.

Walleye Capital LLC purchased a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,380 shares of the company's stock, valued at approximately $307,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC increased its position in Janux Therapeutics by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 9,033 shares of the company's stock valued at $244,000 after acquiring an additional 3,168 shares during the last quarter. New York State Common Retirement Fund boosted its position in Janux Therapeutics by 3.0% in the 1st quarter. New York State Common Retirement Fund now owns 16,435 shares of the company's stock worth $444,000 after purchasing an additional 471 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Janux Therapeutics during the fourth quarter worth about $6,216,000. California State Teachers Retirement System grew its holdings in Janux Therapeutics by 82.2% in the 4th quarter. California State Teachers Retirement System now owns 36,735 shares of the company's stock valued at $1,967,000 after buying an additional 16,575 shares in the last quarter. Finally, KBC Group NV purchased a new position in shares of Janux Therapeutics during the 1st quarter worth $66,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Up 4.1%

NASDAQ JANX traded up $0.99 on Monday, reaching $24.97. The company had a trading volume of 741,939 shares, compared to its average volume of 917,319. Janux Therapeutics, Inc. has a 52-week low of $21.97 and a 52-week high of $71.71. The stock has a market capitalization of $1.50 billion, a P/E ratio of -13.85 and a beta of 2.84. The company's fifty day moving average is $24.53 and its 200 day moving average is $26.61.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). On average, research analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JANX. Raymond James Financial assumed coverage on Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 price target on the stock. Guggenheim initiated coverage on Janux Therapeutics in a report on Wednesday. They set a "buy" rating and a $72.00 target price on the stock. Finally, Piper Sandler started coverage on Janux Therapeutics in a research note on Monday, August 18th. They issued an "overweight" rating and a $42.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $85.55.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.